An Open Label, Multi-part drug-drug interaction study to evaluate the effects of rolapitant on the Pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects

Trial Profile

An Open Label, Multi-part drug-drug interaction study to evaluate the effects of rolapitant on the Pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Rolapitant (Primary) ; Dextromethorphan; Efavirenz; Omeprazole; Repaglinide; Tolbutamide
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 09 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top